George Han, MD, PhD

In "The Next Five Years in Psoriasis: Remission, Access, and Combinations," the panel looks ahead to the advances and the unfinished work of the coming years.

"The Patient Who Is Better but Not Clear: Shared Decisions in Psoriasis" takes up the common scenario of a patient content with partial improvement.

In "Putting On-Treatment Remission Into Practice: A Patient-Defined Target in Psoriasis," the panel returns to remission and grounds it in what patients actually live with.

In "Real-World Evidence and Systemic Inflammation in Psoriasis," our experts scrutinize the evidence behind popular claims about disease progression.

This episode, "IL-17 Inhibitor Safety in Psoriasis: Candidiasis, IBD, and Mental Health," features the panel putting the class's safety signals in context.

In "BE BOLD Head-to-Head: IL-17 vs IL-23 for Psoriasis and PsA," the panel digs into the trial that broke the usual non-inferiority pattern.

"Exploring the IL-17 vs IL-23 Debate in Psoriasis " takes up a deliberately provocative question from the moderator.

In "IL-17 vs IL-23: Head-to-Head Data in Psoriasis and PsA," our experts turn to the trials clinicians actually reach for when choosing a class.

This episode, "Targeting the Pathways: TNF, IL-17, and IL-23 in Psoriasis," features the panel unpacking the biology behind today's biologics.

In "Defining On-Treatment Remission in Psoriasis and PsA," the panel examines whether clear should now mean completely clear.

"Breaking Down Silos: Rheum-Derm Collaboration in Psoriasis Care" takes up the question of how two specialties can stop working in isolation.

Most psoriatic arthritis is preceded by psoriasis, which puts dermatologists on the front line of early detection. The panel details which patients warrant a closer look and how to screen efficiently.

Plaque psoriasis has reached total clearance for many patients, yet psoriatic arthritis still lags behind. The panel opens by mapping where the two halves of psoriatic disease diverge.

Medical experts share their final thoughts on the future of atopic dermatitis treatment with oral systemic agents.

Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.

Medical experts discuss how often patients with atopic dermatitis request treatment breaks, their monitoring approach during these breaks, and how to educate and counsel patients about treatment breaks and rescue treatments, including identifying suitable candidates.

Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.

Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.

Medical experts evaluate the role of biologics in atopic dermatitis, including their efficacy and safety, and discuss reasons for switching between systemic treatments.

Medical experts discuss the significance of speed in achieving itch relief when choosing a treatment for atopic dermatitis.

Medical experts review and comment on the effectiveness of oral JAK inhibitors in providing itch relief for patients with atopic dermatitis.

Medical experts discuss long-term data for other systemic agents in atopic dermatitis and how this information informs their treatment decisions.

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.

Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.

After a brief introduction, medical experts review the pathophysiology of atopic dermatitis and explain how JAK inhibitors modulate this inflammatory condition.

In this MEDcast episode, Raj Chovatiya, MD, PhD, and George Han, MD, PhD, interview Brett King, MD, PhD, to discuss the latest advances in the treatment of alopecia areata.

In this MEDcast episode,Raj Chovatiya, MD, PhD, and George Han, MD, PhD interview Vivian Shi, MD, FAAD, to discuss the latest clinical evidence on the management of atopic dermatitis (AD) in different age groups and patient factors to consider when selecting a treatment for AD.

Expert dermatologists discuss the importance of continued education for physicians treating patients with alopecia areata.